Data suggest that patients in remission with baricitinib 4 mg daily dose who have taken this medication for at least 1 year may be able to attempt baricitinib dose-tapering while continuing their methotrexate regimen.
All articles by Cindy Lampner, MSLIS
The American College of Rheumatology and the National Psoriasis Foundation have released 2018 joint recommendations for the treatment of psoriatic arthritis.
Latest News Your top articles for SundayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses